📰Stockhead: Tryptamine Therapeutics has bolstered its clinical development team with two key appointments as it progresses lead drug candidate IV-infused psilocin TRP-8803, including a world-first trial. $TYP $TYPTF #biotech #health #ASXnews stockhead.com.au/health/tryptam…

Tryptamine Therapeutics (#ASX: $TYP) has commenced patient recruitment for its world-first clinical trial using TRP-8803 (IV #psilocin) with #psychotherapy to treat Binge Eating Disorder. 12 patients will be dosed, with initial results expected Q4 CY2025. announcements.asx.com.au/asxpdf/2025072…

📰Proactive Australia: $TYP has launched patient recruitment for a first-of-its-kind clinical trial assessing TRP-8803, an IV-infused psilocin, as a potential treatment for Binge Eating Disorder (BED). #health #psychedelics #biotech #ASX #ASXnews proactiveinvestors.com.au/companies/news…

Tryptamine Therapeutics (#ASX: $TYP) has commenced patient recruitment for its world-first clinical trial using TRP-8803 (IV #psilocin) with #psychotherapy to treat Binge Eating Disorder. 12 patients will be dosed, with initial results expected Q4 CY2025. announcements.asx.com.au/asxpdf/2025072…

📰Stockhead: Tryptamine Therapeutics has kicked off patient recruitment for its world-first psilocin trial targeting Binge Eating Disorder (BED), with dosing set to start this quarter and a shot at unlocking a massive market. $TYP $TYPTF #biotech #ASX stockhead.com.au/health/tryptam…

ICYMI: Stockhead: Tryptamine Therapeutics has kicked off patient recruitment for its world-first psilocin trial targeting Binge Eating Disorder (BED), with dosing set to start this quarter and a shot at unlocking a massive market. $TYP $TYPTF #biotech stockhead.com.au/health/tryptam…

June Quarterly Activities Report World-first BED trial with TRP-8803 underway. ✔️ Ethics approval secured ✔️ Patient recruitment ongoing ✔️ First dosing this quarter ✔️ Top-line results expected Q4 CY25 Read more: cdn-api.markitdigital.com/apiman-gateway… $TYP $TYPTF #psychedelic #health

ICYMI: June Quarterly Activities Report World-first BED trial with TRP-8803 underway. ✔️ Ethics approval secured ✔️ Patient recruitment ongoing ✔️ First dosing this quarter ✔️ Top-line results expected Q4 CY25 Read more: cdn-api.markitdigital.com/apiman-gateway… $TYP $TYPTF #psychedelic #health

Tryp Therapeutics has received regulatory approval to supply TRP-8803 for its world-first BED trial with Swinburne. First dosing expected this quarter, with top-line results in Q4 2025. Patient screening & enrolment are well underway. cdn-api.markitdigital.com/apiman-gateway… $TYP #Psychedelics

Tryp Therapeutics has received regulatory approval to supply TRP-8803 for its world-first BED trial with Swinburne. First dosing expected this quarter, with top-line results in Q4 2025. Patient screening & enrolment are well underway. cdn-api.markitdigital.com/apiman-gateway… $TYP #Psychedelics

Tryptamine Therapeutics (#ASX: $TYP) secures $2.6m non-dilutive R&D facility, boosting cash reserves to fast-track TRP-8803 clinical trials including the world-first BED study. Read more: cdn-api.markitdigital.com/apiman-gateway… #Biotech #Health #ClinicalTrials

Just the Facts: Tryptamine secures $2.6M R&D loan to advance binge eating disorder drug @tryptherapeutic proactiveinvestors.com/companies/news… #BingeEatingDisorder #Biotech #Psilocybin #Psilocin #ASX #Psychedelics #DrugDevelopment #MedicalResearch

ICYMI: Tryptamine Therapeutics (#ASX: $TYP) secures $2.6m non-dilutive R&D facility, boosting cash reserves to fast-track TRP-8803 clinical trials including the world-first BED study. Read more: cdn-api.markitdigital.com/apiman-gateway… #Biotech #Health #ClinicalTrials

📰Proactive: Tryptamine Therapeutics Ltd (#ASX: $TYP, OTC: $TYPTF) has strengthened its cash position with a $2.6 million research and development (R&D) loan facility from Rockford Equity Pty Ltd. Read more 👇proactiveinvestors.com.au/companies/news…

📰Proactive: Tryptamine Therapeutics Ltd (#ASX: $TYP, OTC: $TYPTF) has strengthened its cash position with a $2.6 million research and development (R&D) loan facility from Rockford Equity Pty Ltd. Read more 👇proactiveinvestors.com.au/companies/news…

🧠Tryp Therapeutics signed an exclusive agreement with Prof. Carhart-Harris & Prof. Mediano (Imperial College London) to develop an EEG-based biomarker platform, leveraging cortical entropy to optimise TRP-8803 in precision psychiatry. announcements.asx.com.au/asxpdf/2025082… #biotech $TYP $TYPTF

Just The Facts: Tryptamine Therapeutics inks landmark deal to advance precision psychiatry @tryptherapeutic proactiveinvestors.com/companies/news… #EEGBiomarkers #EEG #TryptamineTherapeutics #Biomarker #Tryptamine #PsychedelicResearch #MentalHealthCare

🧠Tryp Therapeutics signed an exclusive agreement with Prof. Carhart-Harris & Prof. Mediano (Imperial College London) to develop an EEG-based biomarker platform, leveraging cortical entropy to optimise TRP-8803 in precision psychiatry. announcements.asx.com.au/asxpdf/2025082… #biotech $TYP $TYPTF

📰Stockhead: Tryptamine Therapeutics struck an exclusive deal with world-leading $psychedelic researchers Professor Robin Carhart-Harris and Professor Pedro Mediano to develop a first-of-its-kind EEG based brain entropy biomarker. $TYP $TYPTF #Health stockhead.com.au/health/tryptam…

📰Proactive: Tryptamine Therapeutics signs exclusive agreement to validate EEG-based biomarker for precision psychiatry Full story: proactiveinvestors.com.au/companies/news… #biotech $TYP $TYPTF #psychiatry #news